Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge.
Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in a number of malignancies, including prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the therapeutic implications of targeting it.
Written by:
Elfiky AA, Jiang Z Are you the author?
Aymen A. Elfiky, Dana-Farber Cancer Institute, 44 Binney Street Boston, Massachusetts, 02115, USA
Reference: Curr Cancer Drug Targets. 2012 Nov 21(Epub ahead of print)
doi:
PubMed Abstract
PMID: 23215719
